menu
    • menu
    [{"orgOrder":0,"company":"Berlin Chemie","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"GERMANY","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Dalteparin sodium","moa":"Antithrombin-III","graph1":"Hematology","graph2":"Phase III","graph3":"Berlin Chemie","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Berlin Chemie \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Berlin Chemie \/ Undisclosed"},{"orgOrder":0,"company":"University of Aarhus","sponsor":"Aarhus University Hospital | Leo Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"DENMARK","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Dalteparin sodium","moa":"Antithrombin-III","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase IV","graph3":"University of Aarhus","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Aarhus \/ Aarhus University Hospital | Leo Pharma","highestDevelopmentStatusID":"11","companyTruncated":"University of Aarhus \/ Aarhus University Hospital | Leo Pharma"},{"orgOrder":0,"company":"Centre Hospitalier Universitaire de Saint Etienne","sponsor":"Leo Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Dalteparin sodium","moa":"Antithrombin-III","graph1":"Oncology","graph2":"Phase II","graph3":"Centre Hospitalier Universitaire de Saint Etienne","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Centre Hospitalier Universitaire de Saint Etienne \/ Leo Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Centre Hospitalier Universitaire de Saint Etienne \/ Leo Pharma"},{"orgOrder":0,"company":"Academisch Medisch Centrum - Universiteit van Amsterdam","sponsor":"Netherlands Organisation for Scientific Research | Aspen API | CHU of Saint Etienne: French Ministry of Health Grant | Rotunda Hospital: Definitive Interventions and Feasibility Awards (DIFA) 2017 (sponsor of the Irish part of the study))","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Dalteparin sodium","moa":"Antithrombin-III","graph1":"Hematology","graph2":"Phase IV","graph3":"Academisch Medisch Centrum - Universiteit van Amsterdam","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Academisch Medisch Centrum - Universiteit van Amsterdam \/ Netherlands Organisation for Scientific Research | Aspen API | CHU of Saint Etienne: French Ministry of Health Grant | Rotunda Hospital: Definitive Interventions and Feasibility Awards (DIFA) 2017 (sponsor of the Irish part of the study))","highestDevelopmentStatusID":"11","companyTruncated":"Academisch Medisch Centrum - Universiteit van Amsterdam \/ Netherlands Organisation for Scientific Research | Aspen API | CHU of Saint Etienne: French Ministry of Health Grant | Rotunda Hospital: Definitive Interventions and Feasibility Awards (DIFA) 2017 (sponsor of the Irish part of the study))"},{"orgOrder":0,"company":"Galician Research Group on Digestive Tumors","sponsor":"Leo Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Dalteparin sodium","moa":"Antithrombin-III","graph1":"Oncology","graph2":"Phase III","graph3":"Galician Research Group on Digestive Tumors","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Galician Research Group on Digestive Tumors \/ Leo Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Galician Research Group on Digestive Tumors \/ Leo Pharma"},{"orgOrder":0,"company":"Sunnybrook Health Sciences Centre","sponsor":"Leo Pharma | Sunnybrook Research Institute","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CANADA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Dalteparin sodium","moa":"Antithrombin-III","graph1":"Hematology","graph2":"Phase IV","graph3":"Sunnybrook Health Sciences Centre","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sunnybrook Health Sciences Centre \/ Leo Pharma | Sunnybrook Research Institute","highestDevelopmentStatusID":"11","companyTruncated":"Sunnybrook Health Sciences Centre \/ Leo Pharma | Sunnybrook Research Institute"},{"orgOrder":0,"company":"Denver Health and Hospital Authority","sponsor":"Eisai Inc","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Dalteparin sodium","moa":"Antithrombin-III","graph1":"Cardiology\/Vascular Diseases","graph2":"Undisclosed","graph3":"Denver Health and Hospital Authority","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Denver Health and Hospital Authority \/ Eisai Inc","highestDevelopmentStatusID":"1","companyTruncated":"Denver Health and Hospital Authority \/ Eisai Inc"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Dalteparin sodium","moa":"Antithrombin-III","graph1":"Nephrology","graph2":"Phase III","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Assistance Publique \u2013 H\u00f4pitaux de Paris","sponsor":"Leo Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"FRANCE","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Dalteparin sodium","moa":"Antithrombin-III","graph1":"Hematology","graph2":"Phase III","graph3":"Assistance Publique \u2013 H\u00f4pitaux de Paris","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Assistance Publique \u2013 H\u00f4pitaux de Paris \/ Leo Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Assistance Publique \u2013 H\u00f4pitaux de Paris \/ Leo Pharma"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"DENMARK","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Dalteparin sodium","moa":"Antithrombin-III","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Leo Pharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Leo Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Leo Pharma","sponsor":"Christine Ribic","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"DENMARK","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Dalteparin sodium","moa":"Antithrombin-III","graph1":"Nephrology","graph2":"Phase IV","graph3":"Leo Pharma","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Leo Pharma \/ Christine Ribic","highestDevelopmentStatusID":"11","companyTruncated":"Leo Pharma \/ Christine Ribic"}]

    Find Clinical Drug Pipeline Developments & Deals for Dalteparin sodium

    Menu

    Dalteparin sodium

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Galician Research Group on Digestive Tumors

                            Country arrow
                            SupplySide West
                            Not Confirmed

                            Galician Research Group on Digestive Tumors

                            Country arrow
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dalteparin sodium

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Leo Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            TINzaparin Prophylaxis in Patients With Metastatic Colorectal Cancer

                            Details : Tinzaparin is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Colorectal Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 23, 2022

                            Lead Product(s) : Dalteparin sodium

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Leo Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Sunnybrook Health Sciences Centre

                            Country arrow
                            SupplySide West
                            Not Confirmed

                            Sunnybrook Health Sciences Centre

                            Country arrow
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dalteparin sodium

                            Therapeutic Area : Hematology

                            Study Phase : Phase IV

                            Sponsor : Leo Pharma | Sunnybrook Research Institute

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Tinzaparin Lead-In to Prevent the Post-Thrombotic Syndrome

                            Details : Tinzaparin is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Venous Thrombosis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 12, 2021

                            Lead Product(s) : Dalteparin sodium

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase IV

                            Sponsor : Leo Pharma | Sunnybrook Research Institute

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Assistance Publique – Hôpitaux de Paris

                            Country arrow
                            SupplySide West
                            Not Confirmed

                            Assistance Publique – Hôpitaux de Paris

                            Country arrow
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dalteparin sodium

                            Therapeutic Area : Hematology

                            Study Phase : Phase III

                            Sponsor : Leo Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Therapeutic Anticoagulation Strategy for Acute Chest Syndrome

                            Details : Innohep (Tinzaparin Sodium) is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Anemia.

                            Product Name : Innohep

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 20, 2015

                            Lead Product(s) : Dalteparin sodium

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase III

                            Sponsor : Leo Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Centre Hospitalier Universitaire de Saint Etienne

                            Country arrow
                            SupplySide West
                            Not Confirmed

                            Centre Hospitalier Universitaire de Saint Etienne

                            Country arrow
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dalteparin sodium

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Leo Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effects of Anticoagulant Preventive Injection in Patients With Blood Cancer

                            Details : Tinzaparin is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Lymphoma.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 09, 2014

                            Lead Product(s) : Dalteparin sodium

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Leo Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Leo Pharma

                            Denmark arrow
                            SupplySide West
                            Not Confirmed

                            Leo Pharma

                            Denmark arrow
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dalteparin sodium

                            Therapeutic Area : Nephrology

                            Study Phase : Phase IV

                            Sponsor : Christine Ribic

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Use of Tinzaparin for Anticoagulation in Hemodialysis

                            Details : Tinzaparin is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Kidney Failure, Chronic.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 28, 2013

                            Lead Product(s) : Dalteparin sodium

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase IV

                            Sponsor : Christine Ribic

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Berlin Chemie

                            Germany arrow
                            SupplySide West
                            Not Confirmed

                            Berlin Chemie

                            Germany arrow
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dalteparin sodium

                            Therapeutic Area : Hematology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy of Bemiparin Versus Enoxaparin in the Treatment of DVT

                            Details : Bemiparin Sodium is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Venous Thrombosis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 18, 2013

                            Lead Product(s) : Dalteparin sodium

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Pfizer Inc

                            U.S.A arrow
                            SupplySide West
                            Not Confirmed

                            Pfizer Inc

                            U.S.A arrow
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dalteparin sodium

                            Therapeutic Area : Nephrology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Use Of Fragmin In Hemodialysis

                            Details : Fragmin (Dalteparin Sodium) is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Kidney Failure, Chronic.

                            Product Name : Fragmin

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 18, 2013

                            Lead Product(s) : Dalteparin sodium

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Academisch Medisch Centrum - Universiteit van Amsterdam

                            Country arrow
                            SupplySide West
                            Not Confirmed

                            Academisch Medisch Centrum - Universiteit van Amsterdam

                            Country arrow
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dalteparin sodium

                            Therapeutic Area : Hematology

                            Study Phase : Phase IV

                            Sponsor : Netherlands Organisation for Scientific Research | Aspen API | CHU of Saint Etienne: French Ministry of Health Grant | Rotunda Hospital: Definitive Interventions and Feasibility Awards (DIFA) 2017 (sponsor of the Irish part of the study))

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Comparison of Low and Intermediate Dose Low-molecular-weight Heparin to Prevent Recurrent Venous Thromboemboli...

                            Details : Nadroparin is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Venous Thrombosis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 11, 2013

                            Lead Product(s) : Dalteparin sodium

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase IV

                            Sponsor : Netherlands Organisation for Scientific Research | Aspen API | CHU of Saint Etienne: French Ministry of Health Grant | Rotunda Hospital: Definitive Interventions and Feasibility Awards (DIFA) 2017 (sponsor of the Irish part of the study))

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            University of Aarhus

                            Country arrow
                            SupplySide West
                            Not Confirmed

                            University of Aarhus

                            Country arrow
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dalteparin sodium

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Phase IV

                            Sponsor : Aarhus University Hospital | Leo Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Can Low Molecular Weight Heparin During Pregnancy With Intrauterine Growth Restriction Increase Birth Weight?

                            Details : Tinzaparin is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Fetal Growth Retardation.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 08, 2011

                            Lead Product(s) : Dalteparin sodium

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Phase IV

                            Sponsor : Aarhus University Hospital | Leo Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Leo Pharma

                            Denmark arrow
                            SupplySide West
                            Not Confirmed

                            Leo Pharma

                            Denmark arrow
                            SupplySide West
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dalteparin sodium

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Long-Term Innohep® Treatment Versus a Vitamin K Antagonist (Warfarin) for the Treatment of Venous Thromboem...

                            Details : Innohep (Tinzaparin Sodium) is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Venous Thromboembolism.

                            Product Name : Innohep

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 25, 2010

                            Lead Product(s) : Dalteparin sodium

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth